Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Managing Brain Mets in Melanoma

July 26th 2018

Considerations for T-VEC Therapy in Metastatic Melanoma

July 26th 2018

Anti PD-1 Therapy in Metastatic Melanoma

July 26th 2018

Treating BRAF-Mutated Metastatic Melanoma

July 26th 2018

Managing Recurrence After Adjuvant Therapy in Melanoma

July 26th 2018

Melanoma: BRAF/MEK-Inhibitors as Adjuvant Therapy

July 26th 2018

Initiating Adjuvant Therapy in Stage 3 Melanoma

July 26th 2018

Adjuvant Therapy in Melanoma: Safety and Efficacy

July 26th 2018

Adjuvant Therapy Options in Melanoma

July 26th 2018

Molecular Testing in Melanoma: BRAF and PD-L1

July 26th 2018

Considerations for Surgery in Melanoma

July 26th 2018

Melanoma Field Continues to Shift With Targeted Therapy, Immunotherapy Approvals

July 26th 2018

Joseph Stilwill, MD, addresses recent advances in melanoma and the focus of research moving forward.

Dr. Weber Discusses Updated Data for CheckMate-238

July 24th 2018

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses updated data for the Checkmate-238 trial.

Dr. Stilwill on Optimal Sequencing in Melanoma

July 24th 2018

Joseph Stilwill, MD, medical oncologist, Sarah Cannon Research Institute, discusses optimal sequencing in melanoma.

Dr. Agarwala on Impact of Combining Entinostat with Pembrolizumab

July 20th 2018

Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of combining entinostat with pembrolizumab (Keytruda) across a number of tumor types.

Dr. Stilwill on Adjuvant Advances in Melanoma

July 5th 2018

Joseph Stilwill, MD, medical oncologist, Sarah Cannon Research Institute, discusses adjuvant advances in the treatment of patients with melanoma.

EU Panel Backs Adjuvant Nivolumab for Melanoma

June 29th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab (Opdivo) as an adjuvant treatment for adult patients with completely resected melanoma with lymph node involvement or metastatic disease

Dr. Postow on the FDA Approval of Encorafenib and Binimetinib in BRAF-Mutant Melanoma

June 27th 2018

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of encorafenib plus binimetinib for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma.

FDA Approves Binimetinib/Encorafenib for BRAF+ Melanoma

June 27th 2018

The FDA has approved the combination of the BRAF inhibitor encorafenib (Braftovi) and the MEK inhibitor binimetinib (Mektovi) for the treatment of patients with BRAF-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test.

FDA Accepts Application for Adjuvant Pembrolizumab for Stage III Melanoma

June 25th 2018

The FDA has accepted a supplemental biologics license application for the use of pembrolizumab as an adjuvant treatment for patients with resected, high-risk stage III melanoma.